Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
PharmacoEconomics
Published in: PharmacoEconomics 9/2001

01-09-2001 | Original Research Article

Cost Effectiveness of Bisoprolol in the Treatment of Chronic Congestive Heart Failure in Sweden

Analysis Using Data from the Cardiac Insufficiency Bisoprolol Study II Trial

Authors: Mr Mattias Ekman, Niklas Zethraeus, Bengt Jönsson

Published in: PharmacoEconomics | Issue 9/2001

Login to get access

Abstract

Objective: To investigate the cost effectiveness of adding the β-blocker bisoprolol to standard treatment in patients with congestive heart failure (CHF).
Design and setting: A cost-effectiveness study was based on the Cardiac Insufficiency Bisoprolol Study II (CIBIS-II), a randomised clinical trial investigating the efficacy of adding bisoprolol to standard therapy of CHF. The cost-effectiveness analysis was carried out from a societal perspective.
Methods: Health effects were measured in terms of years of life gained. On the cost side, treatment costs for pharmaceuticals and hospitalisations were included. Data on healthcare resource consumption from CIBIS-II were used and were combined with average Swedish retail prices for medicines, and average costs for hospitalisations based on hospital admissions, in the base case. The costs of added years of life, i.e. consumption net of production during life-years gained were also included.
Results: If costs of added years of life were not included, then bisoprolol therapy increased life expectancy at an incremental cost of Swedish kronor (SEK) 13 094 (1999 values) per year of life gained. If costs of added years of life were included, then the incremental cost-effectiveness ratio of bisoprolol therapy was SEK168 858 per year of life gained.
Conclusions: For patients with CHF with the characteristics of those in CIBIS-II, the cost effectiveness of bisoprolol therapy compares favourably with that of other cardiovascular therapies.
Footnotes
1
This price list is available upon request from the Association of Swedish Pharmacies (Apoteket AB, SE-131 88 Stockholm).
 
2
This information is available on request from The Swedish Association of the Pharmaceutical Industry, LIF, Box 17608, SE-118 92 Stockholm.
 
3
Price list available upon request from Linköping University Hospital, SE-581 85 Stockholm.
 
Literature
1.
2.
Erhardt L, Caidahl K, Eriksson H, et al. Hjärtsvikt (Heart Failure). Stockholm: Socialstyrelsen The National Board of Health and Welfare, 1994: SoS report 3
3.
Rydén-Bergsten T, Andersson F. The health care costs of heart failure in Sweden. J Intern Med 1999; 246: 275–84PubMedCrossRef
4.
McMurray J, Davie A. The pharmacoeconomics of ACE inhibitors in chronic heart failure. Pharmacoeconomics 1996; 9: 188–97PubMedCrossRef
5.
Malek M. Health economics of heart failure. Heart 1999; 82 Suppl. IV: IV11–3PubMed
6.
Andrews R, Cowley AJ. Clinical and economic factors in the treatment of heart failure. Pharmacoeconomics 1995; 7: 119–27PubMedCrossRef
7.
SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302CrossRef
8.
SOLVD Investigators. Effect of enalapril on mortality and development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685–91CrossRef
9.
CONSENSUS Trial Study Group. Effects of enalapril on survival in severe congestive heart failure. N Engl J Med 1987; 316: 429–35
10.
Ball SG, AIRE study investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821–8
11.
Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669–77PubMedCrossRef
12.
Paul SD, Kuntz KM, Eagle KA, et al. Cost and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure. Arch Intern Med 1994; 154: 1143–9PubMedCrossRef
13.
van Hout BA, Wielink G, Bonsel GJ, et al. Effects of ACE inhibitors on heart failure in the Netherlands: a pharmacoeconomic model. Pharmacoeconomics 1993; 3: 387–97PubMedCrossRef
14.
Szucs TD. Pharmacoeconomics of angiotensin converting enzyme inhibitors in heart failure. Am J Hypertens 1997; 10: 272S–9SPubMedCrossRef
15.
Erhardt L, Ball S, Andersson F, et al. Cost effectiveness in the treatment of heart failure with ramipril: a Swedish substudy of the AIRE study. Pharmacoeconomics 1997; 12: 256–66PubMedCrossRef
16.
Anderson F, Cline C, Rydén-Bergsten T, et al. Angiotensin converting enzyme inhibitors and heart failure: the consequences of underprescribing. Pharmacoeconomics 1999; 15: 535–50CrossRef
17.
Hobbs FDR. The scale of heart failure: diagnosis and management issues for primary care. Heart 1999; 82 Suppl. IV: IV8–10PubMed
18.
Swedberg K. History of beta blockers in congestive heart failure. Heart 1998; 79 Suppl. 2: S29–30PubMed
19.
Krum H. β-blockers in heart failure: the ‘new wave’ of clinical trials. Drugs 1999; 58: 203–10PubMedCrossRef
20.
McMurray JJV. Major β blocker mortality trials in chronic heart failure: a critical review. Heart 1999; 82 Suppl. IV: IV14–22PubMed
21.
Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349–55PubMedCrossRef
22.
CIBIS Investigators and Committees. A randomised trial of β-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90: 1765–73CrossRef
23.
CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study: a randomised trial. Lancet 1999; 353: 9–13CrossRef
24.
MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999; 353: 2001–7CrossRef
25.
Tsevat J, Duke D, Goldman L, et al. Cost-effectiveness of captopril therapy after myocardial infarction. J Am Coll Cardiol 1995; 26: 914–9PubMedCrossRef
26.
Delea TE, Vera-Llonch M, Richner RE, et al. Cost-effectiveness of carvedilol for heart failure. Am J Cardiol 1999; 83: 890–6PubMedCrossRef
27.
Schädlich PK, Paschen B, Brecht JG. Economic evaluation of the cardiac insufficiency bisoprolol study for the Federal Republic of Germany. Pharmacoeconomics 1998; 13: 147–55PubMedCrossRef
28.
Levy P, Lechat P, Leizorovicz A, et al. A cost-minimization of heart failure therapy with bisoprolol in the French setting: an analysis from the CIBIS trial data. Cardiovasc Drugs Ther 1998; 12: 301–5PubMedCrossRef
29.
Rich MW, Nease RF. Cost-effectiveness analysis in clinical practice: the case of heart failure. Arch Intern Med 1999; 159: 1690–700PubMedCrossRef
30.
Cleland JGF. Health economic consequences of the pharmacological treatment of heart failure. Eur Heart J 1998; 19 Suppl. P: P32–9PubMed
31.
Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ 1997; 16: 1–31PubMedCrossRef
32.
Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 1997; 16: 33–64PubMedCrossRef
33.
Johannesson M, Meltzer D, O’Conor RM. Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of treatment of hypertension. Med Decis Making 1997; 17: 382–9PubMedCrossRef
34.
Luce BR, Manning WG, Siegel JE, et al. Estimating costs in cost-effectiveness analysis. In: Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York (NY): Oxford University Press, 1996: 176–213
35.
Weinstein MC, Manning WG. Theoretical issues in cost-effectiveness analysis. J Health Econ 1997; 16: 121–8PubMedCrossRef
36.
Vårdkostnader och vårdtider 1997 för NordDRG. Stockholm: Centrum för Patientklassificering (Centre for Patient Classification), 1997
37.
Swedberg K, Kjekshus J, Snapinn S. Long-term survival in severe heart failure in patients treated with enalapril: ten year follow-up of CONSENSUS I. Eur Heart J 1999; 20: 136–9PubMedCrossRef
38.
Adams KF, Zannad F. Clinical definition and epidemiology of advanced heart failure. Am Heart J 1998; 135: S204–15PubMedCrossRef
39.
Lipscomb J, Weinstein MC, Torrance GW. Time preference. In: Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. NewYork (NY): Oxford University Press, 1996: 214–46
40.
Kirsch J, McGuire A. Establishing health state valuations for disease specific states: an example from heart disease. Health Econ 2000; 9: 149–58PubMedCrossRef
41.
Statistical Yearbook of Sweden 2000. Stockholm: Statistics Sweden, 2000
42.
Mandelblatt JS, Fryback DG, Weinstein MC, et al. Assessing the effectiveness of health interventions. In: Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York (NY): Oxford University Press, 1996: 135–75
43.
Drummond MF, O’Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press, 1997
44.
Rittenhouse BE. The relevance of searching for effects under a clinical-trial lamppost: a key issue. Med Decis Making 1995; 15: 348–57PubMedCrossRef
45.
Kannel WB, Ho K, Thom T. Changing epidemiological features of cardiac failure. Br Heart J 1994; 72 Suppl.: S3–9PubMedCrossRef
46.
Newhouse JP. US and UK health economics: two disciplines separated by a common language? Health Econ 1998; 7: S79–92PubMedCrossRef
47.
Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000; 20: 332–42PubMedCrossRef
48.
Goldman L, Gordon DJ, Rifkind BM, et al. Cost and health implications of cholesterol lowering. Circulation 1992; 85: 1960–8PubMedCrossRef
49.
Johannesson M, Meltzer D. Some reflections on cost-effectiveness analysis. Health Econ 1998; 7: 1–7PubMedCrossRef
Metadata
Title
Cost Effectiveness of Bisoprolol in the Treatment of Chronic Congestive Heart Failure in Sweden
Analysis Using Data from the Cardiac Insufficiency Bisoprolol Study II Trial
Authors
Mr Mattias Ekman
Niklas Zethraeus
Bengt Jönsson
Publication date
01-09-2001
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 9/2001
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200119090-00002

Other articles of this Issue 9/2001

PharmacoEconomics 9/2001 Go to the issue

Original Research Article

A Multinational Study to Measure the Value that Patients with Cancer Place on Improved Emesis Control Following Cisplatin Chemotherapy

Original Research Article

Different Approaches To Valuing the Lost Productivity of Patients with Migraine

Original Research Article

Cost-Utility Analysis of Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke

Original Research Article

The Economics of HIV Vaccines

Review Article

Impact of Allergic Rhinitis Treatment on Quality of Life

Original Research Article

The Cost of Palliative Care for Hepatocellular Carcinoma in Hong Kong